Lipocine Inc.
LPCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001535955
No open-market purchases or sales by Lipocine Inc. insiders were filed in the last 90 days; 36 institutions reported holding it in 13F filings for Q2 2026, worth $7.63M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Lipocine Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 24 | 21 | −3 |
| Shares | 477.5K | 499.9K | +22.4K (+4.7%) |
| Value | $2.40M | $1.48M | −$915.6K (−38.1%) |
New holders (2)
Institutions that held Lipocine Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Advisers, LP | 56,922 | $169.6K | 0.00% |
| UBS Group AG | 42 | $125 | 0.00% |
Sold out (5)
Institutions that held Lipocine Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Bridgeway Capital Management, LLC | 24,665 | $123.3K |
| Two Sigma Investments, LP | 11,033 | $55.6K |
| Northwestern Mutual Wealth Management Co | 466 | $2.35K |
| NewSquare Capital LLC | 12 | $60 |
| Acadian Asset Management LLC | 83 | $0 |